Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2% – What’s Next?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shot up 5.2% during mid-day trading on Thursday . The company traded as high as $3.42 and last traded at $3.42. 1,043,397 shares changed hands during trading, a decline of 39% from the average session volume of 1,719,907 shares. The stock had previously closed at $3.25.

Wall Street Analyst Weigh In

A number of brokerages recently commented on XERS. HC Wainwright upped their price target on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research note on Monday, November 11th. Piper Sandler lowered Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Monday, November 11th.

Xeris Biopharma Stock Performance

The stock has a market capitalization of $508.37 million, a price-to-earnings ratio of -7.58 and a beta of 2.65. The company has a fifty day simple moving average of $3.23 and a two-hundred day simple moving average of $2.77.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of XERS. Principal Financial Group Inc. increased its stake in shares of Xeris Biopharma by 30.3% in the 3rd quarter. Principal Financial Group Inc. now owns 102,469 shares of the company’s stock valued at $292,000 after purchasing an additional 23,843 shares during the last quarter. Barclays PLC grew its position in Xeris Biopharma by 87.8% in the third quarter. Barclays PLC now owns 324,472 shares of the company’s stock valued at $925,000 after acquiring an additional 151,685 shares during the last quarter. Geode Capital Management LLC raised its stake in Xeris Biopharma by 2.9% during the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after acquiring an additional 93,091 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Xeris Biopharma by 11.7% in the third quarter. Wellington Management Group LLP now owns 471,644 shares of the company’s stock worth $1,344,000 after acquiring an additional 49,535 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Xeris Biopharma during the 3rd quarter valued at approximately $3,197,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.